Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: September 2009

Section 3 - Treatment

Reference

BlackS, RomanGC, GeldmacherDS, et al. Efficacy and tolerability of Donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323–32.
CourtJA, PerryEK, KalariaRN. Neurotransmitter control of the cerebral vasculature and abnormalities in vascular dementia. In: ErkinjunttiT, GauthierS, eds. Vascular Cognitive Impairment. London: Martin Duniz Ltd, 2002; 167–85.
ErkinjunttiT, SkoogI, LaneR, AndrewsC.Rivastigmine in patients with Alzheimer’s disease and concurrent hypertension. Int J Clin Pract 2002; 56: 791–6.
ErkinjunttiT, KurzA, SmallGW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Therap 2003; 25: 1765–82.
FerrisS, GauthierS. Cognitive outcome measures in vascular dementia. In: ErkinjuntiiT, GauthierS, eds. Vascular Cognitive Impairment. London: Martin Duniz Ltd, 2002; 395–400.
GottfriesCG, BlennowK, KarlssonI, WallinA.The neurochemistry of vascular dementia. Dementia 1994; 5: 163–7.
KeverneJS, LowWCR, ZiabrevaI, CourtJA, OakleyAE, KalariaRN.Cholinergic neuronal deficits in CADASIL. Stroke 2007; 38: 188–91.
MesulamM, SiddiqueT, CohenB.Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 2003; 60: 1183–5.
MöbiusHJ, StöfflerA.New approaches to clinical trials in vascular dementia: Memantine in small vessel disease. Cerebrovasc Dis 2002; 13(S2): 61–6.
MorettiR, TorreP, AntonelloRM, CazzatoG.Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001; 8: 361–2.
MorettiR, TorreP, AntonelloRM, CazzatoG, BavaA.Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002; 203: 141–6.
RomanGC, WilkinsonDG, DoodyRS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005; 20: 338–44.
RomanGC, KalariaRJ.Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006; 27: 1769–85.
RosenWG, MohsRC, DavisKL.A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64.
OrgogozoJ-M, RigaudA-S, StöfflerA, MöbiusH-J, ForetteF.Efficacy and safety of Memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834–9.
SawadaT, WhitehousePJ. Regulatory guidelines for antidementia drugs. In: ErkinjunttiT, GauthierS, eds. Vascular Cognitive Impairment. London: Martin Duniz Ltd, 2002; 619–27.
SeldenNR, GitelmanDR, Salamon-MurayamaN, ParrshTB, MesulamMM.Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998; 121: 2249–57.
SwartzRH, SahlasDJ, BlackSE, et al. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperdensities matter?J Stroke Cerebrovasc Dis 2003; 12: 29–36.
TogashiH, MatsumotoK, YoshidaM.Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rat. Neurosci Lett 1994; 166: 117–20.
VintersHV, EllisWG, ZarowC, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000; 60: 658–9.
WilkinsonD, DoodyR, HelmeR, et al. Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003; 61: 479–86.
WilcockG, MöbiusHJ, StöfflerA, on behalf of the MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297–305.
WinbladB, PorotisN.Memantine in severe dementia: results of the 9M-Best Study. Int J Geriatr Psychiatry 1999; 14: 135–46.

References

BennetHP, CorbettA, GadenS, GraysonD, KrilJ, BroeGA. Subcortical vascular disease and functional decline, a 6 year predictor study. J Am Geriatr Soc 2002; 50: 1969–77.
BorellL. The activity life of people with dementia. Dissertation, Karolinska Institutet, 1992.
BoyleP, PaulRH, MoseDJ and CohenRA. Executive impairments predict functional declines in vascular dementia. Clin Neuropsychol 2004; 18: 75–82.
ClareL, WoodsRT, Moniz CookED, OrellM, SpectorA. Cognitive rehabilitation and cognitive training for early stage Alzheimer’s disease and vascular dementia. The Cochrane Database of Systematic Reviews 2003, issue 4. Art no. CD003260.DOI:10.1002/14651858 .CD003260.
CorcoranM, GitlinL. Dementia management – an occupational therapy home based intervention for caregivers. Am J Occup Ther 1992; 46(9): 801–08.
CotterE, BurgioL, StevensA, GitlinL.Correspondence of the functional independence measure (FIM) self care subscale with real-time observations of dementia patients’ ADL performance in the home. Clin Rehab 2002; 16: 36–45.
GauthierS, RockwoodK, GelinasI, et al. Outcome measures for the study of activities of daily living in vascular dementia. Alzheimers Dis Associ Disord 1999; 13(Supp. 3): S143–7.
GiovannettiT, SchmidtK, GalloJ, SestitoN, LibonD.Everyday action in dementia: Evidence for differential deficits in Alzheimers disease versus subcortical vascular dementia. J Int Neuropsychol Soc 2006; 12: 45–53.
GitlinLN, CorcoranM, WinterL, BoyceA, HauckW.A randomized controlled trial of a home environmental intervention; effect on efficacy and upset in caregivers and on daily function of persons with dementia. The Gerontol 2001; 41(1): 4–14.
GitlinLN, SchinfeldS, WinterL, CorcoranM, BoyceA, HauckW.Evaluating home environments of persons with dementia: interrater reliability ad validity of the Home Environment Assessment Protocol (HEAP). Disability Rehab 2002; 24(1/2/3): 59–71.
Gitlin, LN, HauchW, DennisMP, WinterL.Maintenance of effects of the home environmental skill-building program for family caregivers and individuals with Alzheimers disease and related disorders. J Gerontol 2005; 60A(3): 368–74.
JosephssonS, BäckmanL, BorellL, BernspångB, NygårdL, RönnbergL.Supporting everyday activities in dementia; an intervention study. Int J Geriatr Psychiatry 1993; 8: 395–400.
KielhofnerG, BorellL, FreidheimL, et al. Crafting occupational life. In: KielhofnerG, ed. Model of human occupation. Baltimore, MD: Lippincott Williams & Wilkins, 2002.
LawtonM.The functional assessment of elderly people. J Am Geriatr Soc 1971; 19(6): 465–81.
MillerP, ButinD.The role of occupational therapy in dementia – C.O.P.E. (Caregiver Options for Practical Experiences). Int J Geriatr Psychiatry, 2000; 15: 86–9.
National (American) Alzheimers Association, The. Key elements of dementia care. 1997. www.alz.org.
NygårdL. Assessing ADL/IADL in persons with dementia. In: WinbladB, WimoA, JönssonB, KarlssonG, eds. The health economics of dementia. Chichester: John Wiley & Sons Ltd, 1998.
NygårdL.Instrumental activities of daily living: A stepping stone towards Alzheimer’s disease diagnosis in subjects with mild cognitive impairment?Acta Neurol Scand 2003; 107(Suppl. 179): 42–6.
NygårdL.The responses of persons with dementia to challenges in daily activities: A synthesis of findings from empirical studies. Am J Occup Therapy 2004; 58: 435–45.
NygårdL.How can we get access to the experiences of people with dementia? Suggestions and reflections. Scand J Occup Therapy 2006; 13: 101–12.
PohjasvaaraT, MäntyläR, YlikoskiR, KasteM, ErikjunttiT.Clinical features of MRI defined subcortical vascular disease. Alzheimers Dis Assoc Disord 2003; 17: 236–42.
SinghMA.Exercise come of age: Rationale and recommendations for a geriatric exercise prescription. J Gerontol A Biol Med Sci 2002; 57: M262–82.
TuokkoH, MorrisC, EbertP. Mild cognitive impairment and everyday functioning in older adults. Neurocase 2005; 11: 40–7.
VikströmS, Stigdotter-NeelyA, BorellL, JosephssonS. Caregivers’ self-initiated support towards their partners with dementia when performing an everday occupation together at home. Occupation, Participation & Health 2005; 25(4): 149–59.
World Health Organisation (WHO). International classification of impairments, disabilities, and handicaps. Geneva: WHO, 1990.
World Health Organisation, WHO. ICF, International classification of functioning, disability and health. Geneva: WHO, 2001.
WilsonBA, EmslieHC, QuirkK, EvansJJ.Reducing everyday memory and planning problems by means of a paging system: A randomised control and crossover study. J Neurol Neurosurg Psychiatry 2001; 70: 477–82.
WimoA, WinbladB, GrafströmM.The social consequences for families with Alzheimer’s disease patients. Potential impact of new drug treatment. Int J Geriatr Psychiatr 1999; 14: 338–47.
YaffeK, BarnesD, NevittM, LuiLY, CovinskyK. A prospective study of physical activity and cognitive decline in elderly women: Women who walk. Arch Intern Med 2001; 161: 1703–08.

References

AlessiCA, YoonEJ, SchnelleJF, Al SamarraiNR, CruisePA. A randomized trial of a combined physical activity and environment intervention in nursing home residents: do sleep and agitation improve?J Am Geriatr Soc 1999; 47: 784–91.
AlexopoulosG, AbramsR, YoungR, ShamoianC. Cornell scale for depression in dementia. Biol Psychiatry 1988; 23: 271–84.
AllenH, ByrneEJ, SutherlandD, TomensonB, ButterB, BurnsA. Bright light therapy, diurnal rhythm and sleep in dementia. Int Psychogeriatrics 2003; 15(S12): 97–8.
BallardC, O’BrienJT. Behavioural and psychological symptoms. In: Erkinjuntti T, Gauthier S, eds. Vascular cognitive impairment, London: Martin Dunitz, 2002; 237–52.
BallardC, McKeithI, O’BrienJ, et al., Neuropathological substrates of dementia and depression in vascular dementia, with a particular focus on cases with small infarct volumes. Dementia Geriatr Cogn Disord 2000; 11(2): 59–65.
BallardC, NeillD, O’BrienJ, McKeithIG, InceP, PerryR. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Dis 2000a; 59(2): 97–106.
BallardC, Margallo-LanaM, JuszczakE, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: a randomised, placebo-controlled trial. Br Med J 2005; 330(7496): 874.
BallardCG, PatelA, SolisM, LoweK, WilcockG. A one-year follow-up study of depression in dementia sufferers. Br J Psychiatry 1996; 168: 287–91.
BallardC, O’BrienJ, JamesI, SwannA. Dementia: management of behavioral and psychological symptoms. Oxford: Oxford University Press, 2001.
BNF, 2006.
BMJ Publishing Group, RPS Publishing, March 2006. British National Formulary
BrodatyH, AmesD, SnowdonJ, et al. A randomized controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134–43.
BurnsA, RussellE, Stratton-PowellH, TyrrellP, O’Neill P, BaldwinR. Sertraline in stroke-associated lability of mood. Int J Geriat Psychiatry 1999; 14: 681–5.
ByrneJ, BallardC, HolmesC. Sensory stimulation in dementia. An effective option for managing behavioral problems. Br Med J 2002; 325: 1312–13.
CantillonM, BrunswickR, MolinaD, et al., Buspirone vs haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer’s disease. Am J Geriatr Psychiatry 1996; 4: 263–7.
ChanW, LamLC, ChoyCN, LeungVP, LiS, ChiuHF.A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioral and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001; 16: 1156–62.
ChiuE.Vascular burden and BPSD: a reconceptualization. Int Psychogeriatrics 2003; 15(1): 183–6.
ChiuE, YastrubetskayaO, WilliamsM. Pharmacotherapy of mood and behavior symptoms. In: ErkinjunttiT, GauthierS, eds. Vascular cognitive impairment. London: Martin Dunitz, 2002.
CoccaroEF, KramerE, ZemishlanyZ, et al., Pharmacological treatment of non-cognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147: 1640–5.
CohenD, EisdorferC, GorelickP, et al. Psychopathology associated with Alzheimer’s disease and related disorders. J Gerontology 1993; 8(6): M255–60.
Cohen-MansfieldJ, BilligN. Agitated behaviors in the elderly, I: a conceptual review. J Am Geriatr Soc 1986; 34: 711–21.
Cohen-MansfieldJ, WernerP, MarxMS. An observational study of agitation in nursing home residents. Int Psychogeriatr 1989; 1: 153–65.
Cohen-MansfieldJ, Nonpharmacologic interventions for psychotic symptoms in dementia. Psychiatry Neurol 2003; 16: 219–24.
CooperJK, MungasD. Risk factor and behavioral differences between vascular and Alzheimer’s dementias: the pathway to end-stage disease. J Geriatr Psychiatry Neurol 1993; 1: 29–33.
CummingsJL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer’s disease. Am J Psychiatry 1993; 150: 1806–12.
CummingsJL, MegaM, GrayK, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14.
CummingsJL. Vascular subcortical dementias: clinical aspects. Dementia 1994; 5: 177–80.
CummingsJL. Cholinesterase inhibitors: a new class of psychiatric compound. Am J Psychiatry 2000; 157: 4–15.
DeDeynPP, RabheruK, RasmussenA, et al. A randomised trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55.
DevanandDP. Conventional neuroleptics in dementia. Int Psychogeriatr 2000; 12 (suppl 1): 253–61.
DonaldsonC, TarrierN, BurnsA. The impact of the symptoms of dementia on caregivers. Br J Psychiatry 1997; 170: 62–8.
DouglasS, JamesI, BallardC. Non-pharmacological interventions in dementia. Adv Psychiatric Treat 2004; 10: 171–9.
ErkinjunttiT, GauthierS. Vascular cognitive impairment. London: Martin Dunitz, 2002.
ErkinjunttiT, VatajaR, LeppavuoriA. Behavioural and psychological symptoms of dementia and vascular dementia. Int Psychogeriatr 2000; 12 (Suppl 1): 195–200.
FinkelS. Introduction to behavioral and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry 2000; 15: S2–4.
FinkelS, SilvaCE, CohenG, MillerS, SartoriusN. Behavioural and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int J Geriatr Psychiatry 1997; 12: 1060–1.
FujikawaT, TakahashiT, KinoshitaA, et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 2004; 49: 201–04.
GrovesWC, BrandtJ, SteinbergM, et al. Vascular dementia and Alzheimer’s disease: is there a difference? A comparison of symptoms by disease duration. J Neuropsychiatry Clin Neurosci 2000; 12: 305–15.
HawkinsJW, TinklenbergJR, SheikhJI, et al. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriar Psychiatry 2000; 8: 221–5.
HerrmannN. Valproic acid in the treatment of agitation in dementia. Can J Psychiatry 1998; 43: 69–72.
HerrmannN. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 2001, 28: (Suppl 1): S96–107.
HolmbergSK. Evaluation of a clinical intervention for wanderers on a geriatric nursing unit. Arch Psychiatric Nurs 1997; 11: 21–8.
HopeT, KeeneJ, FairburnC, McShaneR, JacobyR. Behaviour changes in dementia 2: are there behavioral syndromes?Int J Geriatr Psychiatry 1997; 12: 1074–8.
HowardR, BallardC, O’BrienJ, BurnsA. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry 2001; 16: 714–17.
JesteDV, CaliguiriMP, PaulsenJS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756–65.
KatzIR, JesteDV, MintzerJE, et al. 1999. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial (Risperidone study group). J Clin Psychiatry 1999; 60: 107–15.
KingAC, OmanRF, BrassingtonGS, BliwiseDL, HaskellWL. Moderate-intensity exercise and self-rated quality of sleep in older adults. A randomised controlled trial. JAMA 1997; 277: 32–7.
KozmanMN, WattisJ, CurranS. Pharmacological management of behavioral and psychological disturbance in dementia. Hum Psychopharmacol Clin Exp 2006; 21: 1–12.
KunikME, HuffmanJC, BharaniMD, HillmanSL, MolinariVA, OrengoCA. Behavioural disturbance in geropsychiatric inpatients across dementia types. J Geriatr Psychiatry Neurol 2000; 13: 49–52.
LawlorB. Managing behavioral and psychological symptoms in dementia. Br J Psychiatry 2002; 181: 463–5.
LawlorB, RadcliffeJ, MolchenSE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s dementia. Int J Geriatr Psychiatry 1994; 9: 55–9.
LavretskyH, ChuiHC. Vascular dementia. In: AgroninME, MalettaGJ, eds. Principles and practice of geriatric psychiatry. Balhimore MD: Lippincott Williams and Wilkins, 2006; 301–10.
LeroiI, VoulgariA, BreitnerJCS, LyketsosCG. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry 2003; 11: 83–91.
LiY-S, MeyerJS, ThornbyJ. Longitudinal follow-up of depressive symptoms among normal versus cognitively impaired elderly. Int J Geriatr Psychiatry 2001; 16: 818–727.
LindK, EdmanA, KarlssonI, SjogrenM, WallinA. Relationship between depressive symptomatology and the subcortical brain syndrome in dementia. Int J Geriatr Psychiatry 2002; 17(8): 774–8.
LivingstonG, JohnstonK, KatonaC, PatonJ, LyketsosCG, Old Age Task Force of the World Federation of Biological Psychiatry. Systematic review of psychological treatment approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162: 1996–2021.
LonerganE, LuxenbergJ, ColfordJ, BirksJ. Haloperidol for agitation in dementia. Cochrane Database of Systematic Reviews, 2002. Issue 2. Art No.: CD002852. DOI: 10.1002/14651858.CD002852.
LyketsosCG, Lindell VeielL, BakerA, SteeleC. A randomized controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Int J Geriatr Psychiatry 1999; 14(7): 520–5.
LyketsosCG, SteinbergM, TschanzJT, NortonMC, SteffensDC, BreitnerJCS. Mental and behavioral disturbances in dementia: findings from the cache county study on memory in aging. Am J Psychiatry 2000; 157: 708–14.
McKeithI. Galantamine for vascular dementia. Lancet Neurol 2002; 1: 210.
McKeithI. Dementia with Lewy bodies. In: AgroninME, MalettaGJ eds. Principles and practice of geriatric psychiatry. Baltimore, MD: Lippincott Williams and Wilkins, 2006; 311–18.
McManusDQ, ArvanitisLA, KowalcykBB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel trial 48 study group. J Clin Psychiatry 1999; 60: 292–8.
McShaneR, KeeneJ, GedlingK, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. Br Med J 1997; 314: 266–70.
MayerR, DarbySJ. Does a mirror deter wandering in demented older people?Int J Geriatr Psychiatry 1991; 6: 607–09.
MillerLJ. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother 2001; 35: 427–31.
MorettiR, TorreP, AntonelloRM, CattaruzzaT, CazzatoG. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: Risks of cerebrovascular events. J Neurol 2005; 252: 1186–93.
MorettiR, TorreP, AntonelloRM, CazzatoG. Behavioural alterations and vascular dementia. The Neurologist 2006; 12(1): 43–7.
NamaziKH, GwinnupPB, ZadoroznyCA. A low intensity exercise/movement program for patients with Alzheimer’s disease: the TEMP-AD protocol. J Aging Phys Activity 1994; 2: 80–92.
National Institute for Health and Clinical Excellence, Social Care Institute for Excellence. Dementia: Supporting people with dementia and their carers in health and social care. NICE clinical guideline 42, November. National Collaborating Centre for Mental Health, 2006.
NewmanSC. The prevalence of depression in Alzheimer’s disease and vascular dementia in a population sample. J Affect Dis 1999; 52: 169–76.
O’BrienJT, ErkinjunttiT, ReisbergB, et al. Vascular cognitive impairment. Lancet Neurol 2003; 2(Feb): 89–98.
O’BrienJ. Behaviours symptoms in vascular cognitive impairment and vascular dementia. Int J Psychogeriatrics 2003; 15(1): 133–8.
O’DonnellBF, DrachmanDA, BarnesHJ, et al. Incontinence and troublesome behaviors predict institutionalisation in dementia. J Geriatr Psychiatry Neurol 1992; 5: 45–52.
OpieJ, RosewarneR, O’ConnorDW. The efficacy of psychosocial approaches to behavior disorders in dementia: a systematic literature review. Aust NZ Psychiatry 1999; 33: 789–99.
OvershottR, BurnsA. Treatment of dementia. J Neurol, Neurosurg Psychiatry 2005; 76 (5): 53–9.
PerrinT. Lifted into a world of rhythm and melody. J Dementia Care 1998; 5: 18–19.
PintoC, SeethalakshmiR. Behavioural and psychological symptoms of dementia in an Indian population: Comparison between Alzheimer’s disease and vascular dementia. Int Psychogeriatrics 2006; 18(1): 87–93.
PorsteinssonAP, TariotPN, ErbR, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 58–66.
PurandareN, AllenNHP, BurnsA. Behavioural and psychological symptoms of dementia. Rev Clin Gerontol 2000; 10: 245–60.
ReisbergB, BorensteinJ, SalobSP, et al. Behavioural symptoms in Alzheimer’s disease – phenomenology and treatment. J Clin Psychiatry 1987; 48(Suppl 5): 9–15.
RobertP. Understanding and managing behavioral symptoms in Alzheimer’s disease and related dementias: Focus on rivastigmine. Curr Med Res Opin 2002; 18(3): 156–71.
RockwoodK, SheaC. Behavioural and psychological symptoms in vascular cognitive impairment. In: BowlerJV, HachinskiV, eds. Vascular cognitive impairment: preventable dementia. Oxford: Oxford University Press, 2003.
RomanGC. Facts, myths, and controversies in vascular dementia. J Neurol Sci 2004; 226: 49–52.
RomanGC. Rivastigmine for subcortical vascular dementia. Expert Rev Neurotherapeutics 2005; 5(3): 309–13.
RoslerM. The efficacy of cholinesterase inhibitors in treating the behavioral symptoms of dementia. Int J Clin Pract 2002; Supplement 127 June: 20–36.
SandbornWD, BendfeldtF, HamdyR. Valproic acid for physically aggressive behavior in geriatric patients. Am J Geriatr Psychiatry 1995; 3: 239–42.
SchneiderLS, TariotPN, DagermanKSet al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2000; 335 (15): 1525–38.
SchneiderLS, DagermanKS, InselP. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 2005; 294: 1934–43.
SivalRC, HaffmansPMJ, JansenPAF, DuursmaSA, EikelenboomP. Sodium valproate in the treatment of aggressive behavior in patients with dementia: A randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002; 17(6): 579–85.
StreetJ, ClarkS, GannonKS. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer’s disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57: 968–77.
SultzerDL, LevinHS, MahlerME, HighWM, CummingsJL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer’s disease. Am J Psychiatry 1993; 150: 1806–12.
SwearerJM, DrachmanDA, O’DonnellBF, MitchellAL. Troublesome and disruptive behaviors in dementia. Relationships to disease severity. J Am Geriatr Soc 1988; 36(9): 784–90.
TariotP, GaileSE, CastelliNA, PorsteinssonAP. Treatment of agitation in dementia. New Direct Mental Hlth Serv 1997; 76: 109–23.
TariotPN. Treatment of agitation in dementia. J Clin Psychiatry 1999; 60 (Suppl 8): 11–20.
TariotPN, ErbR, PodgorskiCA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54–61.
TeriL, LogsdonRG, McCurrySM. Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin N Am 2002; 86: 641–56.
VatajaR, PohjasvaaraT, LeppavuoriA, et al. Magnetic resonance imaging correlates of depression after ischaemic stroke. Arch Gen Psychiatry 2001; 58: 925–31.
WhallAL, BlackME, GrohCJ, YankouDJ, KupferschmidBJ, FosterNL. The effect of natural environments upon agitation and aggression in late-stage dementia patients. Am J Alzheimer’s Dis 1997; 12: 216–20.

References

AevarssonO, SkoogI.A longitudinal population study of the mini-mental state examination in the very old: Relation to dementia and education. Dement Geriatr Cogn Disord 2000; 11(3): 166–75.
AkomolafeA, BeiserA, MeigsJB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 2006; 63(11): 1551–5.
ApplegateWB, PresselS, WittesJ, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994; 154: 2154–60.
Association AH. Control your risk factors for high blood pressure. Available at: http://www.americanheart.org/presenter.jhtml?identifier=581, 2007.
Association AH. Metabolic syndrome. Available at: http://www.americanheart.org/presenter.jhtml?iden tifier=581.
AyanianJZ, ZaslavskyAM, WeissmanJS, SchneiderEC, GinsburgJA. Undiagnosed hypertension and hypercholesterolemia among uninsured and insured adults in the Third National Health and Nutrition Examination Survey. Am J Public Health 2003; 93(12): 2051–4.
BaggerYZ, TankoLB, AlexanderssenP, QinG, ChristiansenC. The implications of body fat mass and fat distribution for cognitive function in elderly women. Obes Res 2004; 12: 1519–26.
Barrett-ConnorE, EdelsteinSL, Corey-BloomJ, WiederholtWC. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 1996; 44: 1147–52.
BlennowK, WallinA, FredmanP, KarlssonI, GottfriesCG, SvennerholmL. Blood–brain barrier disturbance in patients with Alzheimer’s disease is related to vascular factors. Acta Neurol Scand 1990; 81(4): 323–6.
Borjesson-HansonA, EdinE, GislasonT, SkoogI. The prevalence of dementia in 95 year olds. Neurology 2004; 63(12): 2436–8.
BrookRD, BardRL, RubenfireM, RidkerPM, RajagopalanS. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001; 88: 1264–9.
BrubacherD, MonschAU, StahelinHB. Weight change and cognitive performance. Int J Obes Relat Metab Disord 2004; 28(9): 1163–7.
BuchmanAS, WilsonRS, BieniasJL, ShahRC, EvansDA, BennettDA. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005; 65(6): 892–7.
DeMicheleM, PanicoS, IannuzziA, et al. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke 2002; 33(12): 2923–8.
DiazVA, MainousAG 3rd, KoopmanRJ, GeeseyME. Undiagnosed obesity: implications for undiagnosed hypertension, diabetes, and hypercholesterolemia. Fam Med 2004; 36(9): 639–44.
Di BariM, PahorM, FranseLV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 2001; 153(1): 72–8.
Di BariM, PahorM, FranseLV, et al. Evaluation and correction for a “training effect” in the cognitive assessment of older adults. Neuroepidemiology 2002; 21(2): 87–92.
Di BariM, PahorM, BarnardM, et al. Evaluation and correction for a “training effect” in the cognitive assessment of older adults. Neuroepidemiology 2002; 21(2): 87–92.
EliasMF, EliasPK, SullivanLM, WolfPA, D’AgostinoRB. Obesity, diabetes and cognitive deficit: the Framingham Heart Study. Neurobiol Aging 2005; 26(Suppl.1): 11–16.
EnzingerC, FazekasF, MatthewsPM, et al. Risk factors for progression of brain atrophy in aging: Six-year follow-up of normal subjects. Neurology 2005; 64(10): 1704–11.
Expert Panel on the Identification and Treatment of Overweight and Obesity in Adults. Aim for a Healthy Weight. Washington, DC: National Institutes of Health; 2005. 05–5213.
Faxen-IrvingG, BasunH, CederholmT. Nutritional and cognitive relationships and long-term mortality in patients with various dementia disorders. Age Ageing 2005; 34(2): 136–41.
FordES, GilesWH, DietzWH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9.
ForetteF, SeuxML, StaessenJA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352(9137): 1347–51.
ForetteF, SeuxML, StaessenJA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162(18): 2046–52.
GreenwoodCE, WinocurG. High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging 2005; 26(Suppl 1): 42–5.
GreenwoodCE, KaplanRJ, HebblethwaiteS, JenkinsDJ. Carbohydrate-induced memory impairment in adults with type 2 diabetes. Diabetes Care 2003; 26(7): 1961–6.
GrundmanM, Corey-BloomJ, JerniganT, ArchibaldS, ThalLJ. Low body weight in Alzheimer’s disease is associated with mesial temporal cortex atrophy. Neurology 1996; 46(6): 1585–91.
GuoZ, ViitanenM, FratiglioniL, WinbladB. Low blood pressure and dementia in elderly people: the Kungsholmen project. Br Med J 1996; 312(7034): 805–08.
GuoZ, QiuC, ViitanenM, FastbomJ, WinbladB, FratiglioniL. Blood pressure and dementia in persons 75+ years old: 3-year follow-up results from the Kungsholmen Project. J Alzheimer’s Dis 2001; 3(6): 585–91.
GustafsonDRC, KurzerMS. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Mol Biol 1993; 46: 381–8.
GustafsonDRC, RothenbergE, BlennowK, SteenB, SkoogI. An 18-year follow up of overweight and risk for Alzheimer’s disease. Arch Intern Med 2003; 163: 1524–8.
GustafsonD, LissnerL, BengtssonC, BjörkelundC, SkoogI. A 24-year follow-up of body mass index and cerebral atrophy. Neurology 2004a; 63: 1876–81.
GustafsonD, SteenB, SkoogI. Body mass index and white matter lesions in elderly women. An 18-year longitudinal study. Int J Psychogeriatrics 2004b; 16: 327–36.
HanTS, van LeerEM, SeidellJC, LeanME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br Med J 1995; 311(7017): 1401–5.
HanTS, WilliamsK, SattarN, HuntKJ, LeanME, HaffnerSM. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002; 10(9): 923–31.
HausmanDB, DiGirolamoM, BartnessTJ, HausmanGJ, MartinRJ. The biology of white adipocyte proliferation. Obesity Rev 2001; 2: 239–54.
HoganDB, EblyEM, RockwoodK. Weight, blood pressure, osmolarity, and glucose levels across various stages of Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 1997; 8: 147–51.
HöglundK, BlennowK. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer’s Disease. CNS Drugs 2007; 21(6): 449–62.
HouxP, ShepherdJ, BlauwG-J, et al. Testing cognitive function in elderly populations: the PROSPER study. J Neurol Neurosurg Psychiatry 2002; 73: 385–9.
in’t VeldBA, RuitenbergA, HofmanA, StrickerBH, BretelerMM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22(3): 407–12.
JagustW, HarveyD, MungasD, HaanM. Central obesity and the aging brain. Arch Neurol 2005; 62(10): 1545–8.
JeongSK, NamHS, SonMH, SonEJ, ChoKH. Interactive effect of obesity indexes on cognition. Dement Geriatr Cogn Disord 2005; 19(2–3): 91–6.
JormAF, KortenAE, HendersonAS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465–79.
KalmijnS, FoleyD, WhiteL, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. Arterioscler Thromb Vasc Biol 2000; 20: 2255–60.
KannelWB. Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertens 2000; 13: 3S–10S.
KivipeltoM, HelkalaEL, LaaksoMP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. Br Med J 2001; 322(7300): 1447–51.
KivipeltoM, HelkalaEL, LaaksoMP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137(3): 149–55.
KivipeltoM, NganduT, FratiglioniL, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62(10): 1556–60.
LastJ. A Dictionary of Epidemiology. Second edition. New York: Oxford University Press, 1988.
LatheR. Hormones and the hippocampus. J Endocrinol 2001; 169(2): 205–31.
LaunerLJ, RossGW, PetrovichH, et al. Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiol Aging 2000; 21: 49–55.
LeibsonCL, RoccaWA, HansonVA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145: 301–08.
LithellH, HanssonL, SkoogI, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21(5): 875–86.
MartinsIJ, HoneE, FosterJK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry 2006; 11(8): 721–36.
McCrindleBW, UrbinaEM, DennisonBA, et al. Summary of the American Heart Association’s scientific statement on drug therapy of high-risk lipid abnormalities in children and adolescents. Arterioscler Thromb Vasc Biol 2007; 27(5): 982–5.
McGavockJM, VictorRG, UngerRH, SzczepaniakLS. Adiposity of the heart, revisited. Ann Intern Med 2006; 144: 517–24.
MielkeMM, ZandiPP, SjögrenM, et al. Elevated total cholesterol levels in late-life associated with a reduced risk of dementia. Neurology 2005; 64: 1689–95.
MorrisMC, ScherrPA, HebertLE, GlynnRJ, BennettDA, EvansDA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58(10): 1640–6.
National Institutes of Health NH, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report. Bethesda, MD: National Institutes of Health; 1998.
NotkolaIL, SulkavaR, PekkanenJ, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 1998; 17(1): 14–20.
NourhashemiF, AndrieuS, Gillette-GuyonnetS, et al. Is there a relationship between fat-free soft tissue mass and low cognitive function? Results from a study of 7105 women. J Am Geriatr Soc 2002; 50(11): 1796–801.
NourhashemiF, DeschampsV, LarrieuS, LetenneurL, DartiguesJF, Barberger-GateauP. Body mass index and incidence of dementia: the PAQUID study. Neurology 2003; 60(1): 117–9.
OttA, StolkRP, van HarskampF, PolsHA, HofmanA, BretelerMM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53(9): 1937–42.
PangalosMN, JacobsenSJ, ReinhartPH. Disease modifying strategies for the treatment of Alzheimer’s disease targeted at modulating levels of the beta-amyloid peptide. Biochem Soc Trans 2005; 33(Pt 4): 553–8.
PasquierF, BoulogneA, LeysD, FontaineP. Diabetes mellitus and dementia. Diabetes Metab 2006; 32(5 Pt 1): 403–14.
PatelBN, PangD, SternY, et al. Obesity enhances verbal memory in postmenopausal women with Down syndrome. Neurobiol Aging 2004; 25(2): 159–66.
PeartS. Results of MRC (UK) trial of drug therapy for mild hypertension. Clin Invest Med 1987; 10(6): 616–20.
PilcherH. Alzheimer’s disease could be “type 3 diabetes”. Lancet Neurol 2006; 5(5): 388–9.
PosnerHB, TangMX, LuchsingerJ, LantiguaR, SternY, MayeuxR. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002; 58(8): 1175–81.
PrinceMJ, BirdAS, BlizardRA, MannAH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults. Br Med J 1996; 312(7034): 801–05.
PROGRESS, Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.
QiuC, von StraussE, FastbomJ, WinbladB, FratiglioniL. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 2003; 60(2): 223–8.
QureshiAI, SuriMF, GutermanLR, HopkinsLN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161(13): 1621–8.
ReitzC, TangMX, LuchsingerJ, MayeuxR. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61(5): 705–14.
RichardsSS, EmsleyCL, RobertsJ, et al. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 2000; 48(9): 1035–41.
RomasSN, TangMX, BerglundL, MayeuxR. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999; 53(3): 517–21.
RosengrenA, SkoogI, GustafsonD, WilhelmsenL. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005; 165(3): 321–6.
RuitenbergA. Vascular factors in dementia. Observations in the Rotterdam StudyRotterdam: Erasmus University, 2000.
RuitenbergA, SkoogI, OttA, et al. Blood pressure and risk of dementia: results from the Rotterdam Study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12(1): 33–9.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program. JAMA 1991; 265: 3255–64.
SkoogI, NilssonL, PalmertzB, AndreassonL-A, SvanborgA. A population-based study of dementia in 85-year-olds. N Engl J Med 1993; 328: 153–8.
SkoogI, LernfeltB, LandahlS, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
SkoogI, KalariaRN, BretelerMM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13(Suppl 3): S106–14.
SolomonA, KareholtI, NganduT, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 2007; 68(10): 751–6.
SparksDL, ScheffSW, HunsakerJC 3rd, LiuH, LandersT, GrossDR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994; 126(1): 88–94.
StaessenJA, FagardR, ThijsL, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
StewartR, MasakiK, XueQL, et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu–Asia Aging Study. Arch Neurol 2005; 62(1): 55–60.
SuwaidiJA, HiganoST, HolmesDR, LennonR, LermanA. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 2001; 37: 1523–8.
TanZS, SeshadriS, BeiserA, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003; 163(9): 1053–7.
TzourioC, AndersonC, ChapmanN, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–75.
WaldsteinSR, KatzelLI. Interactive relations of central versus total obesity and blood pressure to cognitive function. Int J Obes (Lond) 2006; 30(1): 201–07.
WardMA, CarlssonCM, TrivediMA, SagerMA, JohnsonSC. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol 2005; 5: 23.
WatsonGS, CraftS. Insulin resistance, inflammation, and cognition in Alzheimer’s Disease: Lessons for multiple sclerosis. J Neurol Sci 2006; 245(1–2): 21–33.
WhiteH, PieperC, SchmaderK, FillenbaumG. Weight change in Alzheimer’s disease. J Am Geriatr Soc 1996; 44: 265–72.
WhiteH, PieperC, SchmaderK. The association of weight change in Alzheimer’s Disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998; 46: 1223–7.
WhitmerRA, GundersonEP, Barrett-ConnorE, QuesenberryCP, Jr., YaffeK. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. Br Med J 2005; 330(7504): 1360.
WilliamsIL, WheatcroftSB, ShahAM, KearneyMT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002; 26(6): 754–64.
WuC, ZhouD, WenC, ZhangL, ComoP, QiaoY. Relationship between blood pressure and Alzheimer’s disease in Linxian County, China. Life Sci 2003; 72(10): 1125–33.
XuW, QiuC, WinbladB, FratiglioniL. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes 2007; 56(1): 211–6.
YaffeK, KanayaA, LindquistK, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292(18): 2237–42.
Yki-JärvinenH, WesterbackaJ. Vascular actions of insulin in obesity. Int J Obes Relat Metab Disord 2000; 24: S25–8.
YoshitakeT, KiyoharaY, KatoI, et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995; 45(6): 1161–8.
ZandiP, BreitnerJ, AnthonyJ. Is pharmacological prevention of Alzheimer’s a realistic goal?Expert Opin Pharmacother 2002; 3: 365–80.
ZhangR, ReisinE. Obesity–hypertension: the effects on cardiovascular and renal systems. J Hypertension 2000; 13: 1308–14.

Websites with information on the control of vascular risk factors.

Topic

blood pressure/hypertension

blood cholesterol/hypercholesterolemia

overweight/obesity

Web address

http://www.nhlbi.nih.gov/health/public/heart

http://www.nhlbi.nih.gov/health/public/heart

http://www.americanheart.org

http://www.nhlbi.nih.gov/health/public/heart

http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Obesity